PANTHERx Rare, a medicinal distributor focusing on rare diseases, has teamed up with Gilead Sciences to distribute Livdelzi.
This agreement will allow the therapeutic to be distributed across the US.
The selective peroxisome proliferator-activated receptor delta agonist is approved for treating adults with primary biliary cholangitis (PBC), and is used either in combination with ursodeoxycholic acid (UDCA) or as a monotherapy in those unable to tolerate UDCA.
Primary biliary cholangitis is a chronic and progressive disease that affects the small bile ducts in the liver.
It can results in impaired bile flow, resulting in the accumulation of bile acids in the liver — which then leads of inflammation, injury and cirrhosis of the organ.
The disease is most prevalent in middle aged women, though it can also occur in men.
Livdelzi aims to normalise levels of alkaline phosphatase, which is a common biomarker of liver disease. It also focuses on improving symptoms associated with PBC, allowing patients to preserve and maintain liver function for longer.
PANTHERx's Executive Chairperson, Rob Snyder, commented: "People living with rare and devastating diseases deserve access to treatment options that work for them. The partnership with Gilead Sciences aims to positively impact key clinical outcomes for those suffering from Primary Biliary Cholangitis and we are pleased to be a part in that."
